Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | ||||
| Depreciation Amortization | 85 | 33 | 6 | 0 |
| Accounts receivable | -88 | -11 | -10 | -55 |
| Other Working Capital | -923 | 4 | 237 | 289 |
| Other Operating Activity | -3,962 | -2,967 | -4,081 | -1,466 |
| Operating Cash Flow | $-4,888 | $-2,941 | $-3,848 | $-1,232 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -649 | -120 | -52 | 0 |
| Other Investing Activity | -9 | 23 | -37 | -19 |
| Investing Cash Flow | $-658 | $-97 | $-89 | $-19 |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | N/A | 0 | 111 | 1,119 |
| Debt Repayment | -30 | -28 | -15 | 0 |
| Common Stock Issued | 2,709 | 740 | 2,331 | 2,226 |
| Other Financing Activity | 3,199 | 420 | 1,868 | 118 |
| Financing Cash Flow | $5,878 | $1,132 | $4,295 | $3,463 |
| Exchange Rate Effect | -173 | -16 | -109 | 0 |
| Beginning Cash Position | 541 | 2,463 | 2,214 | 2 |
| End Cash Position | 700 | 541 | 2,463 | 2,214 |
| Net Cash Flow | $332 | $-1,906 | $358 | $2,212 |
| Free Cash Flow | ||||
| Operating Cash Flow | -4,888 | -2,941 | -3,848 | -1,232 |
| Capital Expenditure | -649 | -120 | -52 | N/A |
| Free Cash Flow | -5,537 | -3,061 | -3,900 | -1,232 |